Home › Funds › ARS Investment Partners, LLC › ASND

ARS Investment Partners, LLC position in ASND

ASCENDIS PHARMA A/S · Health Care

ARS Investment Partners, LLC reported holding 206,179 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$47.0M, representing 2.11% of its reported portfolio and ranking #13 among its reported holdings. ARS Investment Partners, LLC has disclosed ASND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)206.18K sh
Reported value held$46.97M
Portfolio Weight2.11%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How ARS Investment Partners, LLC's ASND position evolved

ARS Investment Partners, LLC first disclosed a stake in ASND in Q3 2023 at 285,918 shares (US$26.8M). The position peaked in Q2 2026 at 210,462 shares, worth US$56.1M. Across 13 filings, ARS Investment Partners, LLC increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 206,179 shares valued at US$47.0M — a reduction of -4,283 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 285.92K $26.77M New
Q4 2023 282.74K $35.61M Reduce
Q1 2024 254.97K $38.54M Reduce
Q2 2024 253.14K $34.52M Reduce
Q3 2024 263.11K $39.29M Add
Q4 2024 265.48K $36.55M Add
Q1 2025 265.16K $36.51M Hold
Q2 2025 209.93K $36.23M Reduce
Q3 2025 175.67K $34.92M Reduce
Q4 2025 174.61K $37.23M Reduce
Q1 2026 209.46K $47.91M Add
Q2 2026 210.46K $56.13M Hold
Q3 2026 206.18K $46.97M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 37 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has ARS Investment Partners, LLC held ASND?

ARS Investment Partners, LLC has disclosed ASND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is ARS Investment Partners, LLC's current position in ASND?

As of Q3 2026, ARS Investment Partners, LLC holds 206.18K shares of ASND (ASCENDIS PHARMA A/S), valued at $46.97M, representing 2.11% of its reported portfolio and ranking #13.

Has ARS Investment Partners, LLC been buying or selling ASND?

In the latest 13F filing (Q3 2026), ARS Investment Partners, LLC reduced its position in ASND. The position peaked in Q2 2026 at 210.46K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.